Conference Call with Blue Jet Healthcare Management and Analysts on Q2FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Blue Jet Healthcare announced Q1FY25 results: Revenue from operations for Q1FY25 stood at Rs 1,629 million which de-grew 9.3% on YoY basis compared to Rs 1,795 mnin Q1FY24. Gross Margin improved 2% in Q1FY25 (55% in Q1FY25 vs 53% in Q4FY24). This was due to change in Product Mix during June 24. EBITDA for the quarter came at Rs 443 million, which was down 24.9% YoY compared to Rs 590 million in Q1FY24. EBITDA margin for the quarter came at 27.2% as compared to 32.8% in Q1FY24, down 566 bps YoY. PAT for the quarter was at Rs 378 million, which de-grew 14.4% YoY compared to Rs 441 million in Q1FY24. There was an improvement of 2% as compared to Q4 FY24 due to Gross contribution improvement and rationalization of certain expenses. PAT margin for the quarter came at 23.2% as compared to 24.6% in Q1FY24, down 138 bps YoY. Total Treasury Investment and Cash & Cash Equivalent ason June 24 stands at Rs 3,781 million. Company successfully commissioned Plant 6 at Ambernath for manufacturing of Pharma intermediate with a Capacity of 120 KL and Investment of Rs 900 million. Result PDF
Conference Call with Blue Jet Healthcare Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript.